AR118853A1 - Formulaciones farmacéuticas que contienen proteínas de fusión fc de dominio extracelular de cd80 - Google Patents

Formulaciones farmacéuticas que contienen proteínas de fusión fc de dominio extracelular de cd80

Info

Publication number
AR118853A1
AR118853A1 ARP200101262A ARP200101262A AR118853A1 AR 118853 A1 AR118853 A1 AR 118853A1 AR P200101262 A ARP200101262 A AR P200101262A AR P200101262 A ARP200101262 A AR P200101262A AR 118853 A1 AR118853 A1 AR 118853A1
Authority
AR
Argentina
Prior art keywords
extracellular domain
fusion proteins
pharmaceutical formulations
formulations containing
composition
Prior art date
Application number
ARP200101262A
Other languages
English (en)
Spanish (es)
Inventor
Yong Quan
Original Assignee
Five Prime Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc filed Critical Five Prime Therapeutics Inc
Publication of AR118853A1 publication Critical patent/AR118853A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70532B7 molecules, e.g. CD80, CD86
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027New or modified breeds of vertebrates
    • A01K67/0271Chimeric vertebrates, e.g. comprising exogenous cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00Animals characterised by species
    • A01K2227/10Mammal
    • A01K2227/105Murine
    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01KANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00Animals characterised by purpose
    • A01K2267/03Animal model, e.g. for test or diseases
    • A01K2267/0331Animal model for proliferative diseases
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/32Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Environmental Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ARP200101262A 2019-05-03 2020-05-04 Formulaciones farmacéuticas que contienen proteínas de fusión fc de dominio extracelular de cd80 AR118853A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962842722P 2019-05-03 2019-05-03

Publications (1)

Publication Number Publication Date
AR118853A1 true AR118853A1 (es) 2021-11-03

Family

ID=70847527

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101262A AR118853A1 (es) 2019-05-03 2020-05-04 Formulaciones farmacéuticas que contienen proteínas de fusión fc de dominio extracelular de cd80

Country Status (9)

Country Link
US (1) US20220227834A1 (https=)
EP (1) EP3963079A1 (https=)
JP (1) JP7716988B2 (https=)
AR (1) AR118853A1 (https=)
AU (1) AU2020270395A1 (https=)
CA (1) CA3136831A1 (https=)
MX (1) MX2021013272A (https=)
TW (1) TW202108126A (https=)
WO (1) WO2020227062A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
KR20190139216A (ko) 2017-04-28 2019-12-17 파이브 프라임 테라퓨틱스, 인크. Cd80 세포외 도메인 폴리펩티드를 이용한 치료 방법
US12589132B2 (en) 2019-02-22 2026-03-31 Five Prime Therapeutics, Inc. CD80 extracellular domain Fc fusion proteins for treating PD-L1 negative tumors
WO2026062544A1 (en) * 2024-09-23 2026-03-26 Pfizer Inc. Sirp alpha fusion protein formulation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US10273281B2 (en) 2015-11-02 2019-04-30 Five Prime Therapeutics, Inc. CD80 extracellular domain polypeptides and their use in cancer treatment
US11306144B2 (en) * 2017-08-25 2022-04-19 Five Prime Therapeutics, Inc. B7-H4 antibodies and methods of use thereof

Also Published As

Publication number Publication date
WO2020227062A1 (en) 2020-11-12
AU2020270395A1 (en) 2021-12-23
EP3963079A1 (en) 2022-03-09
JP2022531387A (ja) 2022-07-06
CA3136831A1 (en) 2020-11-12
MX2021013272A (es) 2021-11-17
JP7716988B2 (ja) 2025-08-01
US20220227834A1 (en) 2022-07-21
TW202108126A (zh) 2021-03-01

Similar Documents

Publication Publication Date Title
AR118853A1 (es) Formulaciones farmacéuticas que contienen proteínas de fusión fc de dominio extracelular de cd80
CL2020003392A1 (es) Polipéptidos del dominio extracelular de cd80 y su uso en el tratamiento del cáncer (divisional de la solicitud n° 201801172)
MX2021003554A (es) Proteinas de union a dll3 y metodos de uso.
AR111207A1 (es) Anticuerpos anti-lag3
CO2022011728A2 (es) Composiciones y usos de glp-1
BR112019010265A2 (pt) anticorpos anti_cd137 inovadores e usos dos mesmos
MX2021005887A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina.
EA202091711A1 (ru) ГЕТЕРОЦИКЛИЛАМИНОЗАМЕЩЕННЫЕ ТРИАЗОЛЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ Rho-АССОЦИИРОВАННОЙ ПРОТЕИНКИНАЗЫ
CO2018012096A2 (es) Proteínas de fusión gdf15 y usos de estas
CL2024001715A1 (es) Anticuerpo aislado que se une a la proteína e del virus del dengue; y uso.
UY40226A (es) Proteina insecticida quimérica, polinucleotido que la codifica, célula, composición semilla y planta
PE20081214A1 (es) Anticuerpo especifico prlr y sus usos
PE20211202A1 (es) Composiciones de glp-1 y sus usos
CR11648A (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
MX383614B (es) Proteinas de union triespecificas y metodos de uso.
BR112017001940A2 (pt) proteínas de fusão de interleucina-2/receptor alfa de interleucina-2 e processos de uso
MX2018006181A (es) Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer.
BR112016011224A2 (pt) Formulação líquida de uma proteína de fusão que compreende tnfr e região de fc
BR112022000855A2 (pt) Moduladores de nlrp3
MX2023013515A (es) Inhibidores de la interaccion de menina-mll.
EA201992586A1 (ru) Способы лечения с помощью полипептидов внеклеточного домена cd80
BR112021014566A2 (pt) Moduladores de gpr35
EA202092695A1 (ru) Композиции, содержащие глюкозу и гемицеллюлозу, и их применение
CO2020016014A2 (es) Formulación de proteína de fusión ctla4-ig
CL2020002519A1 (es) Composiciones de erenumab y usos de las mismas

Legal Events

Date Code Title Description
FB Suspension of granting procedure